Heart Failure Clinics
-
Publication Venue For
- Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events.. 18:597-607. 2022
- Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease.. 18:625-634. 2022
- Imaging Cardiovascular Emergencies: Real World Clinical Cases.. 16:331-346. 2020
- Sleep Breathing Disorders in Heart Failure.. 16:45-51. 2020
- Heart Failure with Preserved Ejection Fraction in Older Adults.. 13:485-502. 2017
- Cardiac Dysfunction and Heart Failure in Hematopoietic Cell Transplantation Survivors: Emerging Paradigms in Pathophysiology, Screening, and Prevention.. 13:337-345. 2017
- Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators.. 13:139-151. 2017
- Cardiorenal Interactions.. 12:335-347. 2016
- End-of-life Heart Failure Care in the United States.. 11:615-623. 2015
- Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations.. 11:591-601. 2015
- Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study.. 11:581-589. 2015
- The Impact of Worsening Heart Failure in the United States.. 11:603-614. 2015
- Assessing the Quality and Comparative Effectiveness of Team-Based Care for Heart Failure: Who, What, Where, When, and How.. 11:499-506. 2015
- Team-Based Care for Managing Cardiac Comorbidities in Heart Failure.. 11:407-417. 2015
- Potential applications of pharmacogenomics to heart failure therapies.. 10:599-606. 2014
- The role of heart failure pharmacotherapy after left ventricular assist device support.. 10:653-660. 2014
- Heart failure and depression.. 10:295-304. 2014
- Sleep-disordered breathing in patients with heart failure.. 10:243-250. 2014
- Noncardiac comorbidities and acute heart failure patients.. 9:359-vii. 2013
- Optimal utilization and management of implanted cardiac rhythm devices in patients hospitalized for heart failure.. 9:321-vi. 2013
- The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure.. 9:331-vii. 2013
- Data sources for heart failure comparative effectiveness research.. 9:1-13. 2013
- The economics of heart failure.. 9:93-106. 2013
- Congenital heart disease and pulmonary hypertension.. 8:427-445. 2012
- Prognostication in Pulmonary Arterial Hypertension. 8:373-383. 2012
- Biomarkers as surrogate end points in heart failure trials.. 7:501-507. 2011
- Cardiorenal syndrome clinical trial end points.. 7:519-528. 2011
- Clinical trials in acute decompensated heart failure--over 50 years of research.. 7:xv-xvii. 2011
- Clinical trials in mechanical circulatory support.. 7:457-466. 2011
- Conduct of clinical trials in acute heart failure: regional differences in heart failure clinical trials.. 7:539-544. 2011
- Covariate adjustment in heart failure randomized controlled clinical trials: a case analysis of the HF-ACTION trial.. 7:497-500. 2011
- End point selection in acute decompensated heart failure clinical trials: economic end points.. 7:529-537. 2011
- Imaging surrogate end points in heart failure trials.. 7:509-518. 2011
- Lessons learned from clinical trials in acute heart failure: phase 3 drug trials.. 7:451-456. 2011
- Pharmacogenetics in heart failure trials.. 7:553-559. 2011
- Clinical trial evidence for treatment of depression in heart failure.. 7:81-88. 2011
- Epidemiology of cardiorenal syndrome.. 6:333-346. 2010
- Targeting heart failure therapeutics: a historical perspective.. 6:11-23. 2010
- Evaluation of ischemic heart disease.. 5:315-v. 2009
- Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance.. 5:349-vi. 2009
- Translating evidence into practice: use of statins in real-world patients with heart failure.. 4:217-223. 2008
- Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly.. 3:477-484. 2007